Diageo plc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Diageo plc trades at $87.58 (market cap $47.67B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.32 (market cap $2.27B). The key difference: Diageo plc is far larger — about 21× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Diageo plc pays a 2.3% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| DEO | SLS | |
|---|---|---|
Market Cap | $47.67B | $2.27B |
Volume | 893,372 | 4,179,659 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $15.46 |
52-Week Low | $72.47 | $1.39 |
Typical Hold Time | 66 Days | — |
Enterprise Value | $68.09B | $2.14B |
Dividend Yield | 2.3% | — |
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $84.73, down slightly by 0.06% on the day, with a bearish technical signal from moving averages. The company shows solid profitability with a 59.47% gross margin and has beaten EPS estimates in the last three quarters. Recent news highlights marketing initiatives and a CFO transition planned for 2027, while analyst consensus leans positive with 49% buy ratings.
The outlook is mixed: cost-cutting and brand investments support a turnaround, but declining 2026 revenue and net income projections pose risks. Valuation ratios like P/E of 27.19 suggest premium pricing, requiring execution success to justify. Key risks include U.S. market challenges and regulatory scrutiny in regions like India.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →